Streetbeat News

Products Services

URGN

UroGen Pharma announced positive topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:26 pm

DASH

DoorDash is reportedly developing an AI chatbot to expedite the food ordering process, according to Bloomberg. The move is aimed at improving customer experience and efficiency.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 7:21 pm

VIEW

View Inc. has been granted a European patent for 'Power Distribution Networks for Electrochromic Devices (Smart Windows)'.

Portfolio Pulse from Benzinga Newsdesk

July 27, 2023 | 6:55 pm

CARR

EMR

WHR

President Joe Biden has issued a 'Hazard Alert' to protect workers from the ongoing heatwave in the U.S. and pledged to invest in combating the impact of extreme weather events. The air conditioning market is expected to grow significantly due to the increasing demand caused by climate change. U.S.-based companies Carrier Global Corp, Whirlpool Corporation, and Emerson Electric Co are seeing positive trends, while non-U.S.-based companies like Electrolux AB, Hitachi Ltd, Mitsubishi Electric ADR, and Toshiba Corp are also experiencing favorable pricing trends.

Portfolio Pulse from AJ Fabino

July 27, 2023 | 6:05 pm

SOUN

Culper Research has released a report criticizing SoundHound AI, Inc. (SOUN), accusing the company of misleading investors about its AI technology and contract backlog. The report claims that SOUN's technology does not work as advertised, and that its $336M contract backlog is overstated. Culper Research is short on SOUN.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 5:34 pm

LGND

Ligand Pharmaceuticals (NASDAQ:LGND) and its collaborator Merck have announced positive results from two Phase 3 trials of V116, a 21-valent pneumococcal conjugate vaccine designed for adults. If approved, V116 would be the first of its kind. The vaccine uses Ligand's patent-protected Pelican Expression Technology™ platform, and Ligand is entitled to a royalty on worldwide net sales if the vaccine is approved.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 5:32 pm

GILD

The European Commission has approved Gilead Sciences' Trodelvy for the treatment of pre-treated HR+/HER2- metastatic breast cancer. The approval is based on the Phase 3 TROPiCS-02 study, which showed a statistically significant and clinically meaningful overall survival benefit of 3.2 months versus comparator single-agent chemotherapy. Trodelvy also demonstrated a 34% reduction in risk of disease progression or death.

Portfolio Pulse from Happy Mohamed

July 27, 2023 | 5:24 pm

PLNHF

The Arizona Department of Health Services has issued a recall for products sold by two cannabis businesses due to Aspergillus contamination. Nevada's cannabis regulators approved LA Lounge LLC as the first independent location not connected to a dispensary. Planet 13 Holdings Inc. (OTCQX:PLNHF) and Cheyenne Medical Sammy Davis, doing business as Thrive Cannabis Marketplace, were also approved to open such venues. In New Mexico, applicants for cannabis businesses are not getting a federal FBI criminal background check. In Alabama, the validity of Steven Stokes' position as chairman of the Alabama Medical Cannabis Commission is being challenged.

Portfolio Pulse from Jelena Martinovic

July 27, 2023 | 5:23 pm

LLY

Eli Lilly announced successful results from two phase 3 studies of its obesity drug, tirzepatide. The studies showed that participants achieved up to 26.6% mean weight loss. The safety profile was similar to previously reported trials and approved incretin-based therapies. The most common adverse events were mild to moderate gastrointestinal-related issues. Following the news, Eli Lilly's shares rose by 0.90%.

Portfolio Pulse from Vandana Singh

July 27, 2023 | 5:08 pm

MRK

Merck & Co Inc has announced positive results from two Phase 3 trials for its investigational 21-valent pneumococcal conjugate vaccine, V116. The vaccine showed statistically significant immune responses compared to PCV20 in vaccine-naïve adults and was immunogenic for all 21 pneumococcal serotypes in adults who had received a pneumococcal vaccine at least a year before the study. The safety profile of V116 was comparable to the comparator.

Portfolio Pulse from Vandana Singh

July 27, 2023 | 5:05 pm